GlaxoSmithKline has released genomic profiling data for over 300 cancer cell lines via the NCI’s cancer Bioinformatics Grid™ (caBIG™).
The genomic data being shared by GSK through caBIG come from cell lines derived from a wide variety of tumors, including breast, prostate, lung, and ovarian cancers.
The NCI launched the caBIG initiative in 2004 to accelerate the research and discovery of new approaches to the detection, diagnosis, treatment, and prevention of cancer. Since that time, more than 200 organizations and 1,000 individuals have helped to create more than 40 biomedical research tools such as caArray, the microarray data-management system that is guiding the annotation and supporting the exchange of the cancer cell array data provided by GSK.
Biobanking Emerging as a Key Growth Area
Uniting Efforts in Molecular Medicine
Evaluating Data Flow in Systems Biology